This information sheet presents important facts about viral hepatitis A, B, and C. For all three hepatitis types, it provides information regarding vaccines, statistics, where the virus is found in the body, how it is spread, what happens when a person is infected, and public health strategies.
This information sheet discusses treatment for latent TB infection. It reminds patients to keep their weekly medical visits, explains directly observed therapy, provides a list of items to discuss with their doctor, a medication schedule, and advises them to call the doctor immediately if they experience any of the side effects on the list. The information sheet also includes space for the doctor's and clinic's name and telephone number.
This information sheet discusses multidrug-resistant TB (MDR TB), a strain of TB that is resistant to at least two of the best anti-TB drugs, isoniazid and rifampicin. It describes TB disease, MDR TB, extensively drug resistant TB (XDR TB), TB transmission, how drug resistance happens, and who is at risk for getting MDR TB. The information sheet also explains how MDR TB can be prevented, TB vaccine, the symptoms of TB disease, and what an individual should do after being exposed to someone with TB.
This document is intended for use as a reference manual for clinicians caring for persons with or at high risk for TB disease or infection. It is not meant to provide detailed answers to all public health or clinical questions about TB, and it is not meant as a substitute for any specific guidelines.
This information sheet discusses the once-a-week 12-week treatment of rifapentine and isoniazid for latent TB infection (LTBI). It explains LTBI, why it is necessary to treat it, the treatment plan and how it is managed, and a chart for tracking. It also includes hints on how to take the medicine including eating before taking it and avoiding alcohol, and describes normal side effects and possible problems including which signs and symptoms require you to call the doctor or nurse and what to do when taking a dose of medicine in the absence of medical staff.
This infographic, in the form of an information sheet, highlights the impact, causes, and consequences of STDs among young people – and what they can do to protect themselves. While STDs affect individuals of all ages, STDs take a particularly heavy toll on young people. CDC estimates that youth ages 15-24 make up just more than 25 percent of the sexually active population, but account for half of the 20 million new STIs that occur in the United States each year. The infographic provides statistics on gonorrhea, chlamydia, HPV, genital herpes, HIV, and syphilis.
There are more tools to effectively prevent HIV than ever before. Since no single strategy provides complete protection or is right for all individuals, a combination of methods is needed to help reduce HIV transmission. CDC and its partners are currently pursuing a High-Impact Prevention approach to reducing the continued toll of HIV. This approach seeks to use the best mix of proven, cost-effective, and scalable interventions for high-risk populations and areas of the nation (see "Future of HIV Prevention" fact sheet for information).
This information sheet provides an overview of HIV/AIDS in the United States, including the number of persons with the disease. It states that the number of new infections has remained stable, but that an estimated 50,000 persons who become newly infected every year is too high. It notes that nearly 15,000 people with AIDS still die each year in the United States. The information sheet provides statistics on the heavily affected populations by risk group and race/ethnicity.
